A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 757456 Administered Subcutaneously to Healthy Volunteers

Trial Profile

A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 757456 Administered Subcutaneously to Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2018

At a glance

  • Drugs IONIS AGT LRx (Primary) ; Spironolactone
  • Indications Hypertension
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 01 May 2018 Planned End Date changed from 31 Jan 2019 to 31 Aug 2018.
    • 01 May 2018 Planned primary completion date changed from 1 Nov 2018 to 30 May 2018.
    • 01 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top